| Trial | Title | Study Record Detail | Phase | Sponsor/Colaborator |
|---|---|---|---|---|
| A Study of DCDS4501A in Combination With Rituximab, Cyclophosphamide, Doxorubicin and Prednisone in Patients With B-Cell Non-Hodgkin’s Lymphoma | NCT01992653 | Phase II | Genentech Inc./Roche, F. Hoffmann-La Roche Ltd. | |
| A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | NCT01290549 | Phase I | Genentech Inc./Roche, F. Hoffmann-La Roche Ltd. | |
| A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin’s Lymphoma | NCT01691898 | Phase II | Genentech Inc./Roche, F. Hoffmann-La Roche Ltd. | |
| A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | NCT02257567 | Phase II | Genentech Inc./Roche, F. Hoffmann-La Roche Ltd. |
Last Editorial Review: July 15, 2016
